PRADAXA (DABIGATRAN EXTILATE) is a blood thinner that was approved for use in the United States in October of 2010 by the U.S. Food & Drug Administration. All blood thinners carry risks of potential side effects and bleeding. However, PRADAXA BLOOD is not easily, or quickly reversible and thus does not have an antidote that has been proven over time. PRADAXA (DABIGATRAN EXTILATE) is new to the pharmaceutical market and gained celebrated status as “the newest” blood thinner for patients in need of anticoagulant therapy. It also gained popularity because it was advertised as requiring little maintenance or upkeep. Additionally, PRADAXA was promoted as not requiring patients to follow dietary restrictions, like WARFARIN, and the related costs of monitoring.
In November 2011, reports emerged of 260 PRADAXA CASES resulting in deaths. Internationally, health authorities raised concerns over the lack of a quick antidote for the onset of unexpected, or bleeding in emergent circumstances.
Most recently, in March 2012, a PRADAXA CASE REPORT emerged that chronicled the death of an 82 year old man in Utah following a fall. Within hours, a small bleed in his brain became uncontrollable and contributed to, or caused his death.
Gabriel F. Zambrano, P.A., is the author and sponsor of this site. Gabriel F. Zambrano, P.A., has initiated investigations of PRADAXA CASES following reports to his office of death(s) involving PRADAXA BLOOD or PRADAXA BLEEDS.